Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia
Tóm tắt
Inotuzumab ozogamicin (InO) is an antibody-drug conjugate composed of a recombinant, humanized immunoglobulin type G, subtype 4 (IgG4) antibody covalently bound to a semisynthetic derivative of calicheamicin via an acid-labile linker. It was developed for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL). Based on the perceived relatively low immunogenicity risk for this product, a standard approach to immunogenicity testing was utilized during the clinical studies. This manuscript describes the analytical aspects of antibody measurement and highlights the immunogenicity data from clinical studies in patients with hematologic malignancies. Anti-drug antibodies (ADAs) were determined using an enzyme-linked immunosorbent assay for patients with NHL and a bridging electrochemiluminescence assay for patients with ALL. ALL patients who tested positive for ADA were also tested for neutralizing antibodies (pivotal studies only) using a cell-based assay. Immunogenicity assays were validated per current industry practice and regulatory guidelines. Positive ADAs were observed in 7 of 164 (4%) patients with ALL during the pivotal trial. Neutralizing antibodies were not detected in any patients with positive ADAs. No ADAs were detected during the phase I/II ALL study. In NHL studies, antibodies to InO were observed in 27 of 630 (4%) patients. InO clearance was similar between ADA-positive and ADA-negative ALL patients. Standard immunogenicity strategy provided data to evaluate impact on InO efficacy, pharmacokinetics, or other clinical parameters in patients. The incidence of ADA to InO is low and is not clinically meaningful.
Tài liệu tham khảo
Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E et al (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 28:2085–2093
Alley SC, Okeley NM, Senter PD (2010) Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 14:529–537
Carrasco-Triguero M, Yi JH, Dere R, Qiu ZJ, Lei C, Li Y et al (2013) Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis 5:1007–1023
Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins. 2009. http://www.bioagilytix.com/wp-content/uploads/2016/02/FDA-GUIDANCE-Assay-Development-Immunogenicity-Testing.pdf. Accessed 27 June 2017.
Committee for Medicinal Products for Human Use. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. London: European Medicines Agency; December 13, 2007. EMEA/CHMP/BMWP/14327/2006
DeAngelo D, Stock W, Stein A, Shustov A, Liedtke M, Schiffer C et al (2017) Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv 1:1167–1180
Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL et al (2013) Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 31:573–583
Gorovits B, Wakshull E, Pillutla R, Xu Y, Manning MS, Goyal J (2014) Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. J Immunol Methods 408:1–12
Hock MB, Thudium KE, Carrasco-Triguero M, Schwabe NF (2015) Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J 17:35–43
Hoofring SA, Lopez R, Hock MB, Kaliyaperumal A, Patel SK, Swanson SJ et al (2013) Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. Bioanalysis 5:1041–1055
Jani D, Marsden R, Mikulskis A, Gleason C, Klem T, Krinos Fiorotti C et al (2015) Recommendations for the development and validation of confirmatory anti-drug antibody assays. Bioanalysis 7:1619–1631
Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W et al (2016) Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375:740–753
Koren E, Zuckerman LA, Mire-Sluis AR (2002) Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. Curr Pharm Biotechnol 3:349–360
Ogura M, Tobinai K, Hatake K, Davies A, Crump M, Ananthakrishnan R et al (2016) Phase I study of inotuzumab ozogamicin combined with R-CVP for relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. Clin Cancer Res 22:4807–4816
Sauerborn M, van Dongen W (2014) Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates. BioDrugs 28:383–391
Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D et al (2008) Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 48:1267–1281
Shor B, Gerber HP, Sapra P (2015) Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol 67:107–116
Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244–3254
Teicher BA, Chari RV (2011) Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 17:6389–6397
Wensel DL, Awwad M, inventors. Wyeth Corp., assignee. Elimination of interference in immunoassays caused by anti-carbohydrate antibodies.: South African patent CA2686206. May 7, 2012
Wyeth-Ayerst. Gemtuzumab Ozogamicin Summary for Presentation to the FDA’s Oncologic Division Advisory Committee 2000 http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3592b2c.pdf. Accessed 23 Jan 2017
Zein N, Sinha AM, McGahren WJ, Ellestad GA (1988) Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240:1198–1201